Urethral cancer historical perspective: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 15: | Line 15: | ||
==Land mark events== | ==Land mark events== | ||
* Total urethrectomy for carcinoma of [[female]] [[urethra]] was performed in the year 1956. <ref name="pmid13567645">{{cite journal |vauthors=SARGENT JW |title=Total urethrectomy for carcinoma of the female urethra |journal=Postgrad Semin Am Urol Assoc North Cent |volume= |issue= |pages=79–83 |date=1956 |pmid=13567645 |doi= |url=}}</ref> | * Total urethrectomy for carcinoma of [[female]] [[urethra]] was performed in the year 1956.<ref name="pmid13567645">{{cite journal |vauthors=SARGENT JW |title=Total urethrectomy for carcinoma of the female urethra |journal=Postgrad Semin Am Urol Assoc North Cent |volume= |issue= |pages=79–83 |date=1956 |pmid=13567645 |doi= |url=}}</ref> | ||
*FDA approved the first [[chemotherapy]] [[drug]] "[[cisplatin]]" for [[Treatment-resistant depression|treatment]] of [[bladder tumors]] in 1978 and the [[drug]] is also being used for the [[Treatment-resistant depression|treatment]] of [[urethral]] [[cancers]].. | *FDA approved the first [[chemotherapy]] [[drug]] "[[cisplatin]]" for [[Treatment-resistant depression|treatment]] of [[bladder tumors]] in 1978 and the [[drug]] is also being used for the [[Treatment-resistant depression|treatment]] of [[urethral]] [[cancers]].. | ||
| Line 21: | Line 21: | ||
*FDA approved the use of live bacterium, [[bacillus Calmette-Guérin]] ([[BCG]]) for [[Treatment-resistant depression|treatment]] and [[Preventive medicine|prevent]] the recurrence of [[superficial]] [[tumors]] in 1990.<ref name="pmid22778725">{{cite journal |vauthors=Askeland EJ, Newton MR, O'Donnell MA, Luo Y |title=Bladder Cancer Immunotherapy: BCG and Beyond |journal=Adv Urol |volume=2012 |issue= |pages=181987 |date=2012 |pmid=22778725 |pmc=3388311 |doi=10.1155/2012/181987 |url=}}</ref> | *FDA approved the use of live bacterium, [[bacillus Calmette-Guérin]] ([[BCG]]) for [[Treatment-resistant depression|treatment]] and [[Preventive medicine|prevent]] the recurrence of [[superficial]] [[tumors]] in 1990.<ref name="pmid22778725">{{cite journal |vauthors=Askeland EJ, Newton MR, O'Donnell MA, Luo Y |title=Bladder Cancer Immunotherapy: BCG and Beyond |journal=Adv Urol |volume=2012 |issue= |pages=181987 |date=2012 |pmid=22778725 |pmc=3388311 |doi=10.1155/2012/181987 |url=}}</ref> | ||
*New [[chemotherapy]] combination regimen including [[gemcitabine]] with [[cisplatin]] is introduced as more effective with less side effects compare to MVAC [[therapy]] in 2000.<ref name="pmid17851853">{{cite journal |vauthors=Als AB, Sengelov L, Von Der Maase H |title=Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule? |journal=Acta Oncol |volume=47 |issue=1 |pages=110–9 |date=2008 |pmid=17851853 |doi=10.1080/02841860701499382 |url=}}</ref> | *New [[chemotherapy]] combination regimen including [[gemcitabine]] with [[cisplatin]] is introduced as more effective with less side effects compare to MVAC [[therapy]] in 2000.<ref name="pmid17851853">{{cite journal |vauthors=Als AB, Sengelov L, Von Der Maase H |title=Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule? |journal=Acta Oncol |volume=47 |issue=1 |pages=110–9 |date=2008 |pmid=17851853 |doi=10.1080/02841860701499382 |url=}}</ref> | ||
* [[Photodynamic therapy|Photodynamic]] therapy is an innovative [[Therapeutic|therapeuti]]<nowiki/>c modality in [[urologic]] [[malignancy]]. <ref name="pmid21708516">{{cite journal |vauthors=Colin P, Estevez JP, Betrouni N, Nevoux P, Puech P, Leroy X, Biserte J, Villers A, Mordon S |title=[Photodynamic therapy and urothelial carcinoma] |language=French |journal=Bull Cancer |volume=98 |issue=7 |pages=769–78 |date=July 2011 |pmid=21708516 |doi=10.1684/bdc.2011.1389 |url=}}</ref> | * [[Photodynamic therapy|Photodynamic]] therapy is an innovative [[Therapeutic|therapeuti]]<nowiki/>c modality in [[urologic]] [[malignancy]].<ref name="pmid21708516">{{cite journal |vauthors=Colin P, Estevez JP, Betrouni N, Nevoux P, Puech P, Leroy X, Biserte J, Villers A, Mordon S |title=[Photodynamic therapy and urothelial carcinoma] |language=French |journal=Bull Cancer |volume=98 |issue=7 |pages=769–78 |date=July 2011 |pmid=21708516 |doi=10.1684/bdc.2011.1389 |url=}}</ref> | ||
==References== | ==References== | ||
Latest revision as of 16:49, 22 January 2019
|
Urethral cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Urethral cancer historical perspective On the Web |
|
American Roentgen Ray Society Images of Urethral cancer historical perspective |
|
Risk calculators and risk factors for Urethral cancer historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Vindhya BellamKonda, M.B.B.S [2]
Overview
Adenocarcinoma of the urethra in females, a rare malignancy was discovered as early as 1945. Case reports of primary urethral cancers in males have been reported as early as 1948.
Historical perspective
- In 1945, adenocarcinoma of the urethra was first discovered and described in females.[1]
- Later in 1948, carcinoma of urethra in males is disovered.[2]
- In 1962, a case of melanosarcoma of urethra is described.[3]
- A case of rhabdomyosarcoma in a 5 year old girl has been described in the year 2007.[4]
- Carcinoma insitu in bladder and urethra among renal transplant patient has been reported in the year 2008.[5]
Land mark events
- FDA approved the first chemotherapy drug "cisplatin" for treatment of bladder tumors in 1978 and the drug is also being used for the treatment of urethral cancers..
- FDA approved the use of live bacterium, bacillus Calmette-Guérin (BCG) for treatment and prevent the recurrence of superficial tumors in 1990.[7]
- New chemotherapy combination regimen including gemcitabine with cisplatin is introduced as more effective with less side effects compare to MVAC therapy in 2000.[8]
- Photodynamic therapy is an innovative therapeutic modality in urologic malignancy.[9]
References
- ↑ Feltes Ochoa JA, Blanco Carballo O, Sánchez Angel T, Villacampa Aubá F, Conde Gallego E (September 2005). "[Adenocarcinoma of the female urethra: report of two cases and bibliography review]". Arch. Esp. Urol. (in Spanish; Castilian). 58 (7): 677–82. PMID 16294793.
- ↑ FEVES LJ, BROUN JR (February 1948). "Primary carcinoma of the male urethra; case report". Northwest Med. 47 (2): 122. PMID 18857371.
- ↑ SIGNORELLI H (April 1962). "[Primary tumors of the male urethra. (Apropos of a case of melanosarcoma of the urethra)]". Presse Med (in French). 70: 1038–40. PMID 13912737.
- ↑ Liu AX, Zhou JH, Jin HM, Zhu CK, Cheng XD (June 2007). "Primary rhabdomyosarcoma of urethra in a 5-year-old girl: case report and literature review". Urology. 69 (6): 1208.e17–9. doi:10.1016/j.urology.2007.03.022. PMID 17572220.
- ↑ Tillou X, Raynal G, Limani K, Saint F, Petit J (December 2008). "[Carcinoma in situ in bladder and urethra among renal transplanted patient: failure of BCG therapy]". Prog. Urol. (in French). 18 (13): 1097–9. doi:10.1016/j.purol.2008.08.002. PMID 19041819.
- ↑ SARGENT JW (1956). "Total urethrectomy for carcinoma of the female urethra". Postgrad Semin Am Urol Assoc North Cent: 79–83. PMID 13567645.
- ↑ Askeland EJ, Newton MR, O'Donnell MA, Luo Y (2012). "Bladder Cancer Immunotherapy: BCG and Beyond". Adv Urol. 2012: 181987. doi:10.1155/2012/181987. PMC 3388311. PMID 22778725.
- ↑ Als AB, Sengelov L, Von Der Maase H (2008). "Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?". Acta Oncol. 47 (1): 110–9. doi:10.1080/02841860701499382. PMID 17851853.
- ↑ Colin P, Estevez JP, Betrouni N, Nevoux P, Puech P, Leroy X, Biserte J, Villers A, Mordon S (July 2011). "[Photodynamic therapy and urothelial carcinoma]". Bull Cancer (in French). 98 (7): 769–78. doi:10.1684/bdc.2011.1389. PMID 21708516.